Omnicell Updates 2025 Guidance and Stock Buyback Plan

Omnicell ( (OMCL) ) has issued an announcement.

On May 22, 2025, Omnicell announced an update to its second quarter and full-year 2025 guidance, reflecting improved profitability due to reduced tariff rates on imports from China. The company also introduced a new $75 million stock repurchase program, indicating confidence in its financial health and commitment to delivering innovative medication management solutions.

The most recent analyst rating on (OMCL) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Omnicell stock, see the OMCL Stock Forecast page.

Spark’s Take on OMCL Stock

According to Spark, TipRanks’ AI Analyst, OMCL is a Neutral.

Omnicell’s stock score of 61 reflects a mixed outlook. The company has a solid financial foundation with strong cash flows and low leverage, but faces challenges with profitability and high valuation metrics. Technical analysis indicates bearish momentum, while the earnings call underscores revenue growth tempered by tariff impacts and profitability issues. The absence of dividends further limits immediate investor appeal.

To see Spark’s full report on OMCL stock, click here.

More about Omnicell

Omnicell, Inc., established in 1992, is a leader in transforming pharmacy and nursing care delivery through a comprehensive portfolio of robotics, smart devices, intelligent software workflows, and data analytics. The company focuses on delivering clinical and business outcomes across all healthcare settings, supporting the vision of the Autonomous Pharmacy.

Average Trading Volume: 684,826

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.35B

See more data about OMCL stock on TipRanks’ Stock Analysis page.